Atorvastatin for reduction of 28-day mortality in severe and critical COVID-19 patients: a randomized controlled trial.

"Declarations Ethics approval and consent to participateOn June 2nd, 2021, we received IRB approval (No. R.21.04.1300) at Mansoura University, Faculty of Medicine. Written informed consent was obtained from the patient or, if the patient was unable to provide consent, from the legal representative. One of the investigators signed two copies of the consent form with the patient or legal representative (one for the investigator and one for the patient). Both the conducting investigator and the patient signed and dated the consent form. Patients or their legal representatives (in the case of unconscious patients) were clearly informed that all patients have equal chances of receiving active treatment or placebo. Consent for publicationAll patients have signed a consent for publication (item 10 in the consent) of anonymized clinical data. The consent form is available as a supplement to the published protocol [15]. Competing interestsAll authors report no financial or other competing interests. Competing interests All authors report no financial or other competing interests."

"Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). We used the institutional resources for conducting the study. Additionally, Delta Pharm Co. (Egypt) supplied the team with Atorvastatin (Atorstat) and placebo for the purpose of the study. The Delta Pharm Co. did not support the study with any additional resources."

"Trial registration Clinical Trial Registry (NCT04952350) on July 1st, 2021. https://clinicaltrials.gov/ct2/show/NCT04952350"